March 2015 Central Nervous System

The new target-specific oral anticoagulants, which include dabigatran, rivaroxaban, apixaban, and edoxaban have demonstrated safety and efficacy in the treatment of venous thromboembolism.

The FDA has approved Xigduo XR (dapagliflozin and metformin HCl extended-release tablets) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

Bipolar disorder can be managed with a variety of FDA-approved pharmacologic treatment options.

Read about the new OTC Products featured in March.

Research has shown that St. John's wort could help patients suffering from depression.

The value of a good night's sleep is often underestimated until one experiences insomnia. Left untreated, insomnia can negatively impact an individual's health, ability to perform routine tasks, and overall quality of life.

Could proponents of this legislation be more interested in protecting market share in the name of patient safety?